Overview
- Anvisa published resolutions registering two EMS products as generics with liraglutide 6 mg/mL in injectable subcutaneous solution, one tied to an obesity indication and one to type 2 diabetes.
- The agency listed both entries as "genérico — registro de medicamento — clone," a simplified pathway that reuses the technical file of EMS’s existing branded products Olire and Lirux.
- The registrations were published on Tuesday and do not mean immediate pharmacy availability because EMS must announce when it will launch the generics and at what price.
- Brazil’s drug price regulator CMED caps the factory price for such generics at no more than 65% of the reference medicine’s authorized value, while sales still require a retained medical prescription under Anvisa rules implemented in 2025.
- The move increases potential competition in the GLP-1 'caneta' market and could pressure retail prices if EMS launches lower-priced versions, but actual patient savings and access will depend on EMS’s commercial choices, taxes and pharmacy pricing policies.